Hologic, Inc. (NASDAQ:HOLX) Given Average Recommendation of “Hold” by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned a consensus recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $87.00.

A number of research firms have weighed in on HOLX. Raymond James increased their target price on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and raised their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Wednesday, April 10th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, UBS Group lifted their price target on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd.

Insider Transactions at Hologic

In related news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 over the last three months. 1.75% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hologic

Large investors have recently added to or reduced their stakes in the company. Nordea Investment Management AB lifted its stake in Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after buying an additional 69,494 shares during the last quarter. Pathstone Family Office LLC grew its holdings in Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after acquiring an additional 25,010 shares during the period. HB Wealth Management LLC boosted its position in shares of Hologic by 18.1% in the 3rd quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 884 shares during the period. Finally, McGuire Investment Group LLC boosted its position in shares of Hologic by 0.3% in the 4th quarter. McGuire Investment Group LLC now owns 139,161 shares of the medical equipment provider’s stock valued at $9,943,000 after purchasing an additional 366 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of Hologic stock opened at $77.54 on Tuesday. The stock has a market cap of $18.20 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00. The firm’s 50-day moving average is $75.64 and its 200 day moving average is $72.42. Hologic has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. Hologic’s revenue was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.07 EPS. Sell-side analysts anticipate that Hologic will post 4.02 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.